Cargando…

Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review

BACKGROUND: Chimeric Antigen Receptor T cell(CAR T-cell) therapy has been a great success in relapsed/refractory acute B lymphoblastic leukemia and B-cell lymphoma. At the same time, there are also related adverse reactions, especially cytokine release syndrome(CRS) and immune effector cell associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jing, Xiao, Yao, Wu, Xue Q., Xiao, Qiong Z., Feng, Chun, Gao, Kai B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927007/ https://www.ncbi.nlm.nih.gov/pubmed/36798130 http://dx.doi.org/10.3389/fimmu.2023.1098815

Ejemplares similares

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
por: Hua, Jingsheng, et al.
Publicado: (2020)

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum]
Publicado: (2020)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
por: Martínez-Romera, Isabel, et al.
Publicado: (2022)

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
por: Mihara, Keichiro, et al.
Publicado: (2017)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

PB2499: BLINATUMOMAB SEQUENTIAL ANTI-CD22 CAR-T CELLS AND HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SUCCESSFUL TREATMENT OF B LYMPHOBLASTIC LEUKEMIA EXTRAMEDULLARY RECURRENCE: A CASE REPORT
por: Yao, Hao, et al.
Publicado: (2023)

Liquid biopsy for disease monitoring after anti‐CD19 chimeric antigen receptor T cell in diffuse large B‐cell lymphoma
por: Maluquer, Clara, et al.
Publicado: (2020)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
por: Fuh, Franklin K, et al.
Publicado: (2017)

Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report
por: Huang, Chen, et al.
Publicado: (2020)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

CD19/CD22 chimeric antigen receptor (CAR) T-cell cocktail therapy following autologous transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma on (18)F-FDG PET/CT: a case description
por: Zhou, Yeye, et al.
Publicado: (2023)

Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis
por: Falini, Lorenza, et al.
Publicado: (2022)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
por: Luanpitpong, Sudjit, et al.
Publicado: (2021)

Transcatheter Arterial Infusion of Autologous CD133(+) Cells for Diabetic Peripheral Artery Disease
por: Zhang, Xiaoping, et al.
Publicado: (2016)

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
por: An, Na, et al.
Publicado: (2016)

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
por: Chen, K H, et al.
Publicado: (2017)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
por: Jin, Xin, et al.
Publicado: (2019)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation
por: Heck, Clarissa, et al.
Publicado: (2021)

Generation and Characterization of Anti-CD34 Monoclonal Antibodies that React with Hematopoietic Stem Cells
por: Aghebati Maleki, Leili, et al.
Publicado: (2014)

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
por: Yang, Fei, et al.
Publicado: (2019)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
por: Morita, Daisuke, et al.
Publicado: (2017)

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
por: Elsallab, Magdi, et al.
Publicado: (2023)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
por: Hu, Yongxian, et al.
Publicado: (2016)

Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017)

Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
por: Chavez, Julio C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_18e9q0kqhjj7saq66rgishph5o